Current anti-diabetic agents and their molecular targets: A review

• Published in: European journal of medicinal chemistry Vol. 152; pp. 436 - 488
• Main Authors: Kerru, Nagaraju, Singh-Pillay, Ashona, Awolade, Paul, Singh, Parvesh
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 25.05.2018
• Subjects: Anti-diabetes; Molecular targets; Structure-activity relationship; Type-II diabetes; Molecular targets; Type-II diabetes; Structure-activity relationship; Anti-diabetes
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2018.04.061

Diabetes mellitus is a medical condition characterized by the body's loss of control over blood sugar. The frequency of diagnosed cases and consequential increases in medical costs makes it a rapidly growing chronic disease that threatens human health worldwide. In addition, its unnerving statistical projections are perilous to both the economy of the nation and man's life expectancy. Type-I and type-II diabetes are the two clinical forms of diabetes mellitus. Type-II diabetes mellitus (T2DM) is illustrated by the abnormality of glucose homeostasis in the body, resulting in hyperglycemia. Although significant research attention has been devoted to the development of diabetes regimens, which demonstrates success in lowering blood glucose levels, their efficacies are unsustainable due to undesirable side effects such as weight gain and hypoglycemia. Over the years, heterocyclic scaffolds have been the basis of anti-diabetic chemotherapies; hence, in this review we consolidate the use of bioactive scaffolds, which have been evaluated for their biological response as inhibitors against their respective anti-diabetic molecular targets over the past five years (2012–2017). Our investigation reveals a diverse target set which includes; protein tyrosine phosphatase 1 B (PTP1B), dipeptidly peptidase-4 (DPP-4), free fatty acid receptors 1 (FFAR1), G protein-coupled receptors (GPCR), peroxisome proliferator activated receptor-γ (PPARγ), sodium glucose co-transporter-2 (SGLT2), α-glucosidase, aldose reductase, glycogen phosphorylase (GP), fructose-1,6-bisphosphatase (FBPase), glucagon receptor (GCGr) and phosphoenolpyruvate carboxykinase (PEPCK). This review offers a medium on which future drug design and development toward diabetes management may be modelled (i.e. optimization via structural derivatization), as many of the drug candidates highlighted show promise as an effective anti-diabetic chemotherapy. [Display omitted] •The review focuses on anti-diabetic targets with their potent molecules.•Evaluation and identification of novel heterocyclic scaffolds inhibiting different anti-diabetic targets.•C structure activity relationship (SAR) studies.•Key binding interactions of potent inhibitor-protein complexes.